SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.

ABSTRACT:

Background

The analysis of bodily fluids using SELDI-TOF MS has been reported to identify signatures of spectral peaks that can be used to differentiate patients with a specific disease from normal or control patients. This report is the 2nd of 2 companion articles describing a validation study of a SELDI-TOF MS approach with IMAC surface sample processing to identify prostatic adenocarcinoma.

Methods

We sought to derive a decision algorithm for classification of prostate cancer from SELDI-TOF MS spectral data from a new retrospective sample cohort of 400 specimens. This new cohort was selected to minimize possible confounders identified in the previous study described in the companion paper.

Results

The resulting new classifier failed to separate patients with prosta

SUBMITTER: McLerran D 

PROVIDER: S-EPMC4332515 | biostudies-literature | 2008 Jan

REPOSITORIES: biostudies-literature